Article
Oncology
Amol Gupta, Ana De Jesus-Acosta, Lei Zheng, Valerie Lee, Ihab Kamel, Dung Le, Michael Pishvaian, Daniel Laheru
Summary: The combination therapy of liposomal irinotecan with 5-FU and LV has shown modest survival benefits in patients with advanced pancreatic adenocarcinoma (PAC). This real-world study aimed to evaluate the efficacy and safety of nal-IRI plus 5FU-LV in PAC patients who progressed on conventional IRI-containing regimens. The interval between conventional IRI and nal-IRI was significantly associated with increased survival outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Hanla A. Park, Dominic Edelmann, Federico Canzian, Tabitha A. Harrison, Xinwei Hua, Qian Shi, Allison Silverman, Martin Schneider, Richard M. Goldberg, Steven R. Alberts, Michael Hoffmeister, Hermann Brenner, Andrew T. Chan, Ulrike Peters, Polly A. Newcomb, Jenny Chang-Claude
Summary: This study aimed to construct polygenic hazard scores (PHS) as predictive markers for oxaliplatin treatment outcome but could not be replicated in an independent cohort.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Kyunghye Bang, Jaekyung Cheon, Jae Ho Jeong, Hyeon-Su Im, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo
Summary: The study demonstrated that nal-IRI plus 5-FU/LV showed modest efficacy and manageable toxicities in patients with mPAC previously treated with conventional irinotecan-containing chemotherapy. The cumulative dose of prior conventional irinotecan therapy may be inversely correlated with the effectiveness of nal-IRI plus 5-FU/LV.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Yeong Hak Bang, Jeong Eun Kim, Ji Sung Lee, Sun Young Kim, Kyu-Pyo Kim, Tae Won Kim, Yong Sang Hong
Summary: The study evaluated the efficacy of bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer, finding that this combination showed significant disease control rates and survival outcomes in patients who had progressed with prior standard treatments.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Takayuki Yoshino, Eiji Oki, Toshihiro Misumi, Masahito Kotaka, Dai Manaka, Tetsuya Eto, Junichi Hasegawa, Akinori Takagane, Masato Nakamura, Takeshi Kato, Yoshinori Munemoto, Fumitaka Nakamura, Hiroyuki Bando, Hiroki Taniguchi, Yasuhiro Sakamoto, Manabu Shiozawa, Masayasu Nishi, Tetsuya Horiuchi, Hisakazu Yamagishi, Junichi Sakamoto, Tsunekazu Mizushima, Atsushi Ohtsu, Masaki Mori
Summary: The study demonstrated that shortening adjuvant therapy duration from 6 to 3 months did not compromise efficacy in Asian patients with colon cancer, and also reduced the rate of long-lasting peripheral sensory neuropathy. In this setting, 3 months of CAPOX therapy is a suitable adjuvant treatment option.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Jim P. Abraham, Daniel Magee, Chiara Cremolini, Carlotta Antoniotti, David D. Halbert, Joanne Xiu, Phillip Stafford, Donald A. Berry, Matthew J. Oberley, Anthony F. Shields, John L. Marshall, Mohamed E. Salem, Alfredo Falcone, Axel Grothey, Michael J. Hall, Alan P. Venook, Heinz-Josef Lenz, Anthony Helmstetter, W. Michael Korn, David B. Spetzler
Summary: The study identified a molecular signature, FOLFOXai, that can predict the efficacy of oxaliplatin-based chemotherapy combined with bevacizumab in patients with metastatic colorectal cancer, with predictive value for treatment adjustment and survival outcomes, and was validated in TRIBE2 samples.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Georgios Gemenetzis, Alex B. Blair, Minako Nagai, Vincent P. Groot, Ding Ding, Ammar A. Javed, Richard A. Burkhart, Elliot K. Fishman, Ralph H. Hruban, Matthew J. Weiss, John L. Cameron, Amol Narang, Daniel Laheru, Kelly Lafaro, Joseph M. Herman, Lei Zheng, William R. Burns, Christopher L. Wolfgang, Jin He
Summary: The study focused on locally advanced pancreatic cancer (LAPC) patients and found that the anatomical stratification system based on regional structures before treatment plays a significant role in determining the likelihood of surgical resection. Surgeons have a better judgment on the potential for surgical exploration based on the LAPC score during the exploratory operation, leading to improved outcomes for LAPC patients.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jong Keon Jang, Jae Ho Byun, Ji Hun Kang, Jung Hee Son, Jin Hee Kim, Seung Soo Lee, Hyoung Jung Kim, Changhoon Yoo, Kyu-pyo Kim, Seung-Mo Hong, Dong-Wan Seo, Song Cheol Kim, Moon-Gyu Lee
Summary: The study evaluated the ability of CT-determined resectability to predict R0 resection in patients with PDAC after neoadjuvant FOLFIRINOX chemotherapy, finding a relatively low sensitivity and specificity. Low-contrast enhancement of soft tissue contacting artery may enhance the ability of CT to predict R0 resection.
EUROPEAN RADIOLOGY
(2021)
Article
Oncology
Ryoji Takada, Kenji Ikezawa, Takuo Yamai, Ko Watsuji, Yusuke Seiki, Yasuharu Kawamoto, Takeru Hirao, Sena Higashi, Makiko Urabe, Yugo Kai, Tasuku Nakabori, Hiroyuki Uehara, Michiyo Kotani, Toshinari Yagi, Miho Kimura, Keisuke Nozaki, Mari Takagi, Kazuyoshi Ohkawa
Summary: The simultaneous intravenous administration of nal-IRI and Levo-LV offers a safe and effective alternative to the conventional method for treating unresectable pancreatic cancer. It reduces the administration time and provides convenience to patients and healthcare workers.
Article
Oncology
Hans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, Timothy Price, Ralf D. Hofheinz, Bernard Nordlinger, Jean-Francois Daisne, Jos Janssens, Baruch Brenner, Hans Reinel, Stephan Hollerbach, Karel Caca, Florian Fauth, Carla V. Hannig, John Zalcberg, Niall Tebbutt, Murielle E. Mauer, Sandrine Marreaud, Manfred P. Lutz, Karin Haustermans
Summary: The PETACC 6 trial investigated the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative capecitabine in locally advanced rectal cancer, but found no improvement in efficacy and instead noted impaired tolerability and feasibility.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Wei Jiang, Qiying Liu, Donglin Yang, Shi-bin Yang
Summary: Irinotecan as an adjunctive therapy to fluorouracil and leucovorin can increase the survival and objective response of patients with colorectal cancer, but it may also lead to an increased incidence of grade >= 3 adverse events.
Article
Oncology
Yasuyuki Kawamoto, Hiroshi Nakatsumi, Kazuaki Harada, Tetsuhito Muranaka, Atsushi Ishiguro, Yoshimitsu Kobayashi, Hideyuki Hayashi, Satoshi Yuki, Kentaro Sawada, Masataka Yagisawa, Shintaro Nakano, Naoya Sakamoto, Yoshito Komatsu
Summary: OX-IRIS is a new combination therapy for unresectable pancreatic ductal adenocarcinoma, with manageable safety and promising anticancer activities. The recommended dose is level -1, with oral administration of S-1 making it more convenient and eliminating the need for continuous 5-FU infusion.
Article
Radiology, Nuclear Medicine & Medical Imaging
Rahul Parghane, Manish Bhandare, Vikram Chaudhari, Vikas Ostwal, Anant Ramaswamy, Sanjay Talole, Shailesh Shrikhande, Sandip Basu
Summary: In GEP-NET patients, Lu-177-DOTATATE therapy can convert unresectable primary tumors into resectable in a moderate fraction of cases. The treatment leads to improved survival rates and progression-free survival, suggesting its potential as a neoadjuvant therapy option.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Oncology
Ruchi Singhal, Sherise C. Rogers, Ji-Hyun Lee, Brian Ramnaraign, Ilyas Sahin, Jesus C. Fabregas, Ryan M. Thomas, Steven J. Hughes, Ibrahim Nassour, Kathryn Hitchcock, Karen Russell, Omar Kayaleh, Anita Turk, Robert Zlotecki, David L. Deremer, Thomas J. George
Summary: For patients with localized pancreatic cancer, a combination of surgical resection and systemic chemotherapy is essential for optimal survivability. While FOLFIRINOX has shown promising results, its adverse effects can be significant. This investigation explores the use of liposomal irinotecan (nal-IRI) to improve drug delivery and reduce toxicity. The NALIRIFOX regimen has the potential to be safer and more effective, especially in the preoperative setting.
Article
Oncology
Shuhei Nagashima, Satoshi Kobayashi, Shotaro Tsunoda, Yui Yamachika, Yuichiro Tozuka, Taito Fukushima, Manabu Morimoto, Makoto Ueno, Junji Furuse, Shin Maeda
Summary: The efficacy and safety of nal-IRI + 5-FU/LV for patients with PDAC are not significantly different for those aged >= 70 years compared to younger patients.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)